- NeOnc Technologies (NTHI, Financial) progresses towards a $50 million strategic partnership with Quazar Investment.
- NTHI included in the Russell Microcap Index, potentially enhancing institutional investment and market liquidity.
- Clinical trials of NEO100â„¢ and NEO212â„¢ are in Phase II with FDA Fast-Track status, protected by patents until 2038.
NeOnc Technologies Holdings, Inc. (NTHI), a company dedicated to pioneering therapeutics for brain and central nervous system cancers, announced a significant development in its strategic growth plans. The company is advancing towards a $50 million strategic partnership with Quazar Investment, following the recent execution of a Sub-License Agreement with its subsidiary, NuroCure, based in Abu Dhabi. This agreement highlights NeOnc's commitment to expanding its presence across the UAE, GCC, and MENA regions.
In addition, NeOnc Technologies has secured a position in the Russell Microcap Index. This inclusion is strategically significant as it is expected to attract more institutional capital, increase passive fund flows, and improve market liquidity for NTHI.
The company's groundbreaking therapeutics, NEO100â„¢ and NEO212â„¢, are currently in Phase II clinical trials and have secured FDA Fast-Track and Investigational New Drug (IND) status. These treatments utilize the proprietary NEOâ„¢ platform which is designed to overcome the blood-brain barrier, a common challenge in treating brain cancers. The patent protection for these novel agents extends until 2038, providing a robust intellectual property foundation for NeOnc's innovations.
NeOnc's Executive Chairman & President, Amir Heshmatpour, will further discuss these developments in a live interview with financial commentator Kenny Polcari on YouTube.com/@Floorstocks, set for July 24, 2025, at 11:00 a.m. ET. This interview represents an opportunity to engage with a broader audience and share the company's progress and future plans.
